Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.45
PTN's Cash-to-Debt is ranked lower than
70% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. PTN: 3.45 )
Ranked among companies with meaningful Cash-to-Debt only.
PTN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48  Med: 96.73 Max: No Debt
Current: 3.45
Equity-to-Asset -0.31
PTN's Equity-to-Asset is ranked lower than
99.99% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. PTN: -0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
PTN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.31  Med: 0.64 Max: 0.95
Current: -0.31
-0.31
0.95
Piotroski F-Score: 4
Altman Z-Score: -10.02
Beneish M-Score: -6.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -347.62
PTN's Operating Margin % is ranked lower than
99.99% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. PTN: -347.62 )
Ranked among companies with meaningful Operating Margin % only.
PTN' s Operating Margin % Range Over the Past 10 Years
Min: -155850  Med: -175.86 Max: -21.25
Current: -347.62
-155850
-21.25
Net Margin % -369.59
PTN's Net Margin % is ranked lower than
99.99% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. PTN: -369.59 )
Ranked among companies with meaningful Net Margin % only.
PTN' s Net Margin % Range Over the Past 10 Years
Min: -208620  Med: -164.52 Max: -12.64
Current: -369.59
-208620
-12.64
ROA % -162.46
PTN's ROA % is ranked lower than
96% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. PTN: -162.46 )
Ranked among companies with meaningful ROA % only.
PTN' s ROA % Range Over the Past 10 Years
Min: -255.21  Med: -75.2 Max: -14.01
Current: -162.46
-255.21
-14.01
ROC (Joel Greenblatt) % -41406.39
PTN's ROC (Joel Greenblatt) % is ranked lower than
99% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. PTN: -41406.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -44524.89  Med: -1491.54 Max: -92
Current: -41406.39
-44524.89
-92
3-Year EBITDA Growth Rate 10.90
PTN's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. PTN: 10.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PTN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -17.05 Max: 14.6
Current: 10.9
0
14.6
3-Year EPS without NRI Growth Rate 16.30
PTN's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. PTN: 16.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PTN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -22.55 Max: 16.3
Current: 16.3
0
16.3
GuruFocus has detected 1 Warning Sign with Palatin Technologies Inc $PTN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PTN Guru Trades in Q1 2016

Jim Simons 147,300 sh (+70.09%)
» More
Q2 2016

PTN Guru Trades in Q2 2016

Jim Simons 217,200 sh (+47.45%)
» More
Q3 2016

PTN Guru Trades in Q3 2016

Jim Simons 199,600 sh (-8.10%)
» More
Q4 2016

PTN Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PTN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325412    SIC: 2834
Compare:NAS:CGIX, OTCPK:EDTXF, NAS:CEMI, AMEX:VNRX, OTCBB:INIS, NAS:BIOC, NAS:HTGM, NAS:SLNO, NAS:CHEK, NAS:TTOO, NAS:VRML, OTCPK:SEOVF, OTCPK:TDLAF, NAS:DRIO, NAS:TROV, NAS:CDNA, OTCPK:LXXGF, NAS:OPGN, NAS:IDXG, OTCPK:TDSGF » details
Traded in other countries:PTNA.Germany,
Headquarter Location:USA
Palatin Technologies Inc is a biopharmaceutical company engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical need and commercial potential.

Palatin Technologies Inc was incorporated in Delaware in 1986. The Company is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia (wasting syndrome) and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases. The Company's main product in development is bremelanotide for the treatment of female sexual dysfunction. It also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. It has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. The Company's main competitors, includes pharmaceutical, biopharmaceutical and biotechnology companies.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 8.18
PTN's Price-to-Owner-Earnings is ranked lower than
99.99% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. PTN: 8.18 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PTN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.38  Med: 6.35 Max: 8.62
Current: 8.18
3.38
8.62
PS Ratio 7.44
PTN's PS Ratio is ranked lower than
99.99% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. PTN: 7.44 )
Ranked among companies with meaningful PS Ratio only.
PTN' s PS Ratio Range Over the Past 10 Years
Min: 0.85  Med: 7.26 Max: 1440
Current: 7.44
0.85
1440
Price-to-Free-Cash-Flow 13.20
PTN's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. PTN: 13.20 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PTN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10  Med: 11.46 Max: 15.16
Current: 13.2
10
15.16
Price-to-Operating-Cash-Flow 13.20
PTN's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. PTN: 13.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PTN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10  Med: 11.46 Max: 15.16
Current: 13.2
10
15.16
EV-to-EBIT -0.62
PTN's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. PTN: -0.62 )
Ranked among companies with meaningful EV-to-EBIT only.
PTN' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.3  Med: -1.6 Max: 19.2
Current: -0.62
-15.3
19.2
EV-to-EBITDA -0.62
PTN's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. PTN: -0.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.4  Med: -1.6 Max: 8.8
Current: -0.62
-26.4
8.8
Current Ratio 0.86
PTN's Current Ratio is ranked lower than
95% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. PTN: 0.86 )
Ranked among companies with meaningful Current Ratio only.
PTN' s Current Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.7 Max: 21.07
Current: 0.86
0.55
21.07
Quick Ratio 0.86
PTN's Quick Ratio is ranked lower than
90% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. PTN: 0.86 )
Ranked among companies with meaningful Quick Ratio only.
PTN' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.7 Max: 21.07
Current: 0.86
0.55
21.07
Days Sales Outstanding 157.07
PTN's Days Sales Outstanding is ranked lower than
99.99% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. PTN: 157.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.08  Med: 15.89 Max: 157.07
Current: 157.07
0.08
157.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.60
PTN's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. PTN: -20.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -114.5  Med: -27.7 Max: 0
Current: -20.6
-114.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.95
PTN's Price-to-Median-PS-Value is ranked lower than
99.99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PTN: 0.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PTN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 1.39 Max: 69
Current: 0.95
0.15
69
Earnings Yield (Greenblatt) % -161.39
PTN's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. PTN: -161.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -161.39  Med: 407.25 Max: 97808.1
Current: -161.39
-161.39
97808.1

More Statistics

Revenue (TTM) (Mil) $10.82
EPS (TTM) $ -0.24
Beta2.40
Short Percentage of Float5.94%
52-Week Range $0.29 - 0.90
Shares Outstanding (Mil)152.80

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 39 24 77 94
EPS ($) -0.07 -0.15 0.04 0.08
EPS without NRI ($) -0.07 -0.15 0.04 0.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PTN

Headlines

Articles On GuruFocus.com
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcas May 16 2017 
Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webc May 11 2017 
Chuck Royce Cuts Second Largest Communications Equipement Holding Jul 07 2015 

More From Other Websites
Edited Transcript of PTN earnings conference call or presentation 16-May-17 3:00pm GMT May 22 2017
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and... May 16 2017
Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and... May 11 2017
Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York... Mar 31 2017
Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for... Mar 20 2017
Palatin Technologies To Present At The 29th Annual ROTH Conference Mar 09 2017
AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study... Feb 27 2017
Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers Feb 22 2017
AMAG Pharmaceuticals Inks $60M Drug Deal Feb 16 2017
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and... Feb 09 2017
Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North... Feb 03 2017
Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy? Feb 02 2017
Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights... Jan 10 2017
AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal Jan 10 2017
AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder Jan 10 2017
Why AMAG Pharmaceuticals, Inc. Is Falling Today Jan 09 2017
How CytRx Corporation (CYTR) Stacks Up Against Its Peers Dec 14 2016
Palatin Technologies Closes on $16.5 Million Financing Dec 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat